Kineticos’ Deal Tracker is intended to provide life science executives with easy access to the most impactful mergers, acquisitions, licensing agreements and other deal related stories.
Week of January 3, 2017
- Takeda in $35M PvP Biologics GI pact, with acquisition in the cards
- Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
- $70M funding sets Neon on course for bright 2017
- J&J in New Year deal mania, takes on NASH candidate with biotech buyout option
- Synthego Raises $41 Million From Investors, Including a Top Biochemist
Week of December 5, 2016
- Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs
- Amgen teams with NPR-famed StoryCorps to collect and share myeloma stories
- Longfellow buys GSK lab building in RTP, intent to find ‘fast-moving’ life science replacement
- Inovio to receive funds from International Vaccine Institute to develop MERS vaccine
- Parker Institute for Cancer Immunotherapy and Cancer Research
Week of November 28, 2016
- AstraZeneca in broad drug deal with Bicycle worth up to $1 billion
- Takeda to build $106M vaccine plant for dengue vax push
- J&J approaches $20B-valued Actelion about takeover deal
- Sanofi Assumes R&D Efforts for Warp Drive Aminoglycoside Antibiotics
- Axial Biotherapeutics raises $19.15M to target gut-brain axis
Week of November 14, 2016
- Grünenthal buys Thar to expand late-phase pain pipeline
- Bionical Acquires Global Clinical Research Organization Emas Pharma
- Glycomine, Inc. Announces $12 Million Series A Financing to Advance a New Generation of Replacement Therapies for Rare Diseases
- Atlas, Third Rock join forces to launch new stem cell upstart
- Syntimmune gains final $8 million in Series A funding, adds Boehringer, Pfizer vet as new CEO
Week of November 7, 2016
- Celgene pays Juno $50M as it drives deeper into a $1B CAR-T collaboration
- Bristol-Myers’ deepens focus on fibrosis with Nitto deal
- Siemens Healthineers acquires Conworx Technology GmbH to deliver open connectivity for 100+ point-of-care instruments
- IBM Watson, Broad Institute team up on $50M cancer drug resistance project
- Philips and Masimo Sign Multi-Year Business Partnership Agreement in Patient Monitoring and Select Therapy Solutions
Week of October 31, 2016
- Illumina, Q2 Solutions to Collaborate on Companion Dx Development
- Boehringer backs $20M round in ADC cancer player
- Turnstone Biologics Raises $41.4 Million Series B Financing
- Gilead pays $200M milestone to Cambridge biotech Nimbus
- Tryton Medical inks long-term distribution agreement with Cardinal Health
Week of October 24, 2016
- Horizon Pharma Completes Acquisition of Raptor Pharmaceutical Corp.
- Amgen genomics startup wins $40M Series A to follow up deCode in Ireland
- Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics
- Sanofi partners with Brazil to accelerate Zika vaccine work
- Abbott completes deal for Glomed at undisclosed price; picks up two manufacturing plants in Vietnam
- Lilly Buys Pet Vaccines From Boehringer for $885 Million
Week of October 17, 2016
- UNC, Duke nab part of $70 million NIH grants
- Quark Venture, with help from China, sets up $500M life sciences fund in Canada
- Novartis to Develop Cerulean Nanoparticle-Drug Conjugates in Cancer Collaboration
- Lucerno Dynamics raises $6.3M
- Megamerger finalized as ‘QuintilesIMS’ is born
- IBM Watson and German hospital team for rare disease diagnosis
Week of October 10, 2016
- In the midst of an R&D shift, Takeda inks $790M cancer collab with Crescendo
- Helsinn Group Launches $50 Million VC Fund to Back Cancer Startups
- Nitto Denko Acquires Avecia Biotechnology
- PierianDx Acquires Tute Genomics
Week of October 3, 2016
- Teva (TEVA) Pays $160 Million to Celltrion (068270.KQ) in Biosimilar Hook-Up
- Sarepta partners with UK’s Summit on Duchenne drugs
- Fresh off Amgen deal, Arrowhead pairs with microcap Spring Bank in HBV
- Pfizer offloads Hospira infusion therapy unit to ICU Medical for $1B
- AstraZeneca PLC (AZN) Furthers Sell-Off Strategy With New $175 Million Deal
Week of September 26, 2016
- MediGene AG, bluebird bio Partner Up in $1 Billion+ Cancer Immunotherapy Deal
- Hanmi Pharmaceutical Enters into an Exclusive License Agreement with Genentech for a Novel Oral RAF Inhibitor
- SoCal’s Arrowhead Pharma Just Snagged a $673.5 Million Heart Deal With Amgen
- J&J invests in, licenses oncology candidates to microcap Tracon
- Boehringer Partners with Sarah Cannon to Reserach mAbs
- Cambrex Acquires Pharmacore
Week of September 12, 2016
- Allergan pays $639M for Vitae Pharma
- Catalent to acquire Pharmatek
- NIH pours $3M into portable brain injury scanner from Neural Analytics
- Horizon Pharma swoops in on Raptor Pharma with $800M to expand it’s rare disease business
Week of September 5, 2016
- Pfizer did it again, takes a stake in a biotech startup
- Genentech, BioLineRx partner for a checkpoint inhibitor combo
- PPD completes Evidera acquisition, committed to seamless integration
- US CMO, Avara Pharma Services buys AstraZeneca UK plant, saves 210 jobs
- Another Celgene bet pays off as Agios eyes early approval of leukemia drug
Week of August 28, 2016
- Amgen buys rights to Myeloma BiTE immunotherapy from Boehringer Ingelheim
- Elite, Sungen Pharma in development and license agreement
- Sunovion acquires Toronto-based Cynapsus in $624M deal, gains experimental Parkinson’s Drug
- PharmaJet partners with WHO as part of polio eradication effort
- Recipharm, Tillotts Pharma establish long term supply agreement
Week of August 21, 2016
- Pfizer to buy Medivation for $14B
- Pfizer buys AstraZeneca’s Antibiotics Business for $1.5B days after Medivation buy
- Denali snags $130M to bankroll early-stage studies in neurodegenerative drug space
- Dermatology biotech Novan goes for $60M IPO
- SAB Biotherapeutics wins up to $5.3M BARDA contract to develop MERS treatment
Week of August 14, 2016
- Suitors Like Carlyle Group, Hitachi and Permira Line Up for Takeda $1B Unit
- Cryoport Expands Cold Chain Agreement with Stemedica
- Ash Stevens acquired by India-based CDMO
- Eleven Biotherapeutics Inks Multi-, Multi-Million Dollar Deal with Roche
- With new investment, RTP’s Metabolon grows funding to $80 million
Week of August 7, 2016
- Novartis Invests 100M Into France Expansion
- Gilead bags Genmab tech to develop bispecific antibody against HIV
- Allergan to Acquire ForSight VISION5 for 95M
- PPD to acquire evidence-based solutions provider, Evidera
- Catalent wins early-phase contract for Arch’s inhaled orphan drug
Week of July 31, 2016
- Amgen does preclinical I/O tie-up with small cap Advaxis for up to 540M
- Mayne Pharma Commits 80M to North Carolina Expansion after acquiring 42 products form Allergan, Teva
- Quintiles and DaVita Clinical Research announce strategic alliance
- Myriad to acquire Assurex Health for up to 410M
- Catalent Biologics and Zumutor team up
Week of July 24, 2016
- GSK pays up to 230M upfront on J&J deal for asthma antibody
- Boston Scientific snatches up Cosman Medical to gain ground on neuromodulation
- GSK commits to UK manufacturing with 275M in investments at three sites
- China Resources teams up with Macquarie on 1.3B buy of GenesisCare
- LabCorp to acquire prenatal testmaker Sequenom for 371M in cash deal
Week of July 18,2016
- Jounce nabs first big deal in 2.6B I/O tie-up with Celgene
- Amgen and Merck & Co. Invest in Boston’s Akili, Increasing funding round to 42.4M
- Investment group that spun out of Quintiles raises 417M
- ALS upstart Amylyx gains 3M grant to start combo trial
- Japan’s Santen Pharma snaps up glaucoma microshunt maker InnFocus for 225M
Week of July 11, 2016
- Bayer expands discovery deal with PPD spinout X-chem
- Evelo and Epiva Biosciences merge
- Sorrento nabs PD-1 deal with Servier
- Durham’s Patheon moving forward with 580M IPO
- SAGE Therapeutics stock explodes as drug eliminates Postpartum Depression in Mid-Stage Study
Week of July 4, 2016
- SF startup Carmot nabs discovery deal with Genentech
- Sprint Bioscience inks deal worth 243M for PIP4K2-Program with Petra Pharma
- Amicus takes aim at Rare Disease with 90M MiaMed buy
- Bio-Techne to acquire Advanced Cell Diagnostics for up to 325M
- Investors look to the future of AbbVie post-patent protection for Humira
